Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Sirona Biochem ( (TSE:SBM) ) has provided an announcement.
Sirona Biochem has entered into a strategic investment agreement with Promura GmbH, involving a $3 million CAD private placement in convertible debentures and the formation of a joint venture, Sirona Laboratories, in Luxembourg. This partnership aims to enhance Sirona’s market position in anti-aging products and address financial obligations, including a cease trade order, while Promura plans to invest up to $12 million CAD contingent on due diligence.
More about Sirona Biochem
Sirona Biochem is a biotechnology company specializing in cosmetic ingredients and drug discovery, with a focus on stabilizing carbohydrate molecules to enhance efficacy and safety. The company licenses its patented compounds globally, earning licensing fees, milestone fees, and royalties. Its laboratory, TFChem, is based in France and has received multiple scientific awards and grants.
YTD Price Performance: -3.33%
Average Trading Volume: 95,924
Technical Sentiment Signal: Buy
Current Market Cap: C$15.29M
Find detailed analytics on SBM stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue